MARKET

GNMK

GNMK

GenMark
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.86
+0.52
+2.69%
After Hours: 19.86 0 0.00% 17:22 03/08 EST
OPEN
19.68
PREV CLOSE
19.34
HIGH
20.01
LOW
19.18
VOLUME
820.01K
TURNOVER
--
52 WEEK HIGH
23.59
52 WEEK LOW
3.370
MARKET CAP
1.45B
P/E (TTM)
-70.1271
1D
5D
1M
3M
1Y
5Y
Genmark Diagnost Up 38.4% Since SmarTrend Uptrend Call (GNMK)
SmarTrend identified an Uptrend for Genmark Diagnost (NASDAQ:GNMK) on September 21st, 2020 at $13.95. In approximately 6 months, Genmark Diagnost has returned 38.40% as of today's recent price of $19.30.
Comtex SmarTrend(R) · 8h ago
Global Multiplexed Diagnostics Market Share, Size, Top Companies, Demand, Opportunity, Business Strategies Forecast 2025
Mar 03, 2021 (Market Insight Reports) -- Selbyville, Delaware, The ‘ Multiplexed Diagnostics market’ study recently added by Market Study Report, LLC, offers...
Market Insight Reports · 5d ago
Insider Trends: GenMark Diagnostics Sees 90 Days of Insider Buying Trend Scaling Back with Share Sale
MT Newswires · 5d ago
Genmark Diagnost Shares Up 40.3% Since SmarTrend's Buy Recommendation (GNMK)
SmarTrend identified an Uptrend for Genmark Diagnost (NASDAQ:GNMK) on September 21st, 2020 at $13.95. In approximately 5 months, Genmark Diagnost has returned 40.34% as of today's recent price of $19.57.
Comtex SmarTrend(R) · 02/27 10:13
When Can We Expect A Profit From GenMark Diagnostics, Inc. (NASDAQ:GNMK)?
With the business potentially at an important milestone, we thought we'd take a closer look at GenMark Diagnostics...
Simply Wall St. · 02/27 08:32
Global Multiplexed Diagnostics Market - Analysis By Product Type (Consumables, Instruments, Software & Services), End User, By Region, By Country (2020 Edition): Market Insights, COVID-19 Impact, Competition and Forecast (2020-2025)
Feb 26, 2021 (Heraldkeepers) -- Executive Summary Global Multiplexed Diagnostics Market was valued at USD 9213.27 million in the year 2019. Rise in...
Heraldkeepers · 02/26 18:17
GenMark (GNMK) Receives a Hold from Raymond James
Raymond James analyst Andrew Cooper maintained a Hold rating on GenMark (GNMK) today. The company's shares closed last Thursday at $18.80. According to
SmarterAnalyst · 02/26 13:25
The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 25)
Benzinga · 02/26 13:16
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GNMK. Analyze the recent business situations of GenMark through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GNMK stock price target is 22.50 with a high estimate of 24.00 and a low estimate of 21.00.
EPS
Institutional Holdings
Institutions: 242
Institutional Holdings: 75.18M
% Owned: 102.86%
Shares Outstanding: 73.09M
TypeInstitutionsShares
Increased
49
9.57M
New
63
490.22K
Decreased
51
6.71M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-2.17%
Healthcare Equipment & Supplies
-1.34%
Key Executives
Chairman/Independent Director
Kevin O'Boyle
President/Chief Executive Officer/Director
Scott Mendel
Chief Financial Officer
Johnny Ek
Senior Vice President/General Counsel/Secretary
Eric Stier
Senior Vice President/Director of Sales
Michael Harkins
Senior Vice President
Michael Gleeson
Senior Vice President
Tyler Jensen
Senior Vice President
Brian Mitchell
Senior Vice President
Scott O'Brien
Vice President/Director of Human Resources
Hollis Winkler
Independent Director
Daryl Faulkner
Independent Director
Lisa Giles
Independent Director
Michael Kagnoff
Non-Executive Independent Director
James Fox
No Data
About GNMK
GenMark Diagnostics, Inc. is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology. It offers four Food and Drug Administration (FDA)-cleared diagnostic tests which run on its XT-8 instrument; its Respiratory Viral Panel; its Cystic Fibrosis Genotyping Test; its Warfarin Sensitivity Test, and its Thrombophilia Risk Test. It also offers a Hepatitis C (HCV) genotyping test and associated custom manufactured reagents, as well as a 2C19 Genotyping Test, versions of which are available for use with its XT-8 instrument for research use only (RUO). Its XT-8 and ePlex test cartridges utilize the combination of distinct electrodes and multiple signal probes to detect dozens of target biomarkers from a single sample, thereby enabling highly multiplexed testing.

Webull offers kinds of GenMark Diagnostics, Inc stock information, including NASDAQ:GNMK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNMK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GNMK stock methods without spending real money on the virtual paper trading platform.